The global glioblastoma multiforme treatment market size reached US$ 2.1 Billion in 2023. Looking forward, the market is projected to reach US$ 3.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2023-2032.
Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.
Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs.
These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.
This report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.
2. What is the expected growth rate of the global glioblastoma multiforme treatment market during 2024-2032?
3. What are the key factors driving the global glioblastoma multiforme treatment market?
4. What has been the impact of COVID-19 on the global glioblastoma multiforme treatment market?
5. What is the breakup of the global glioblastoma multiforme treatment market based on the route of administration?
6. What is the breakup of the global glioblastoma multiforme treatment market based on the type of molecule?
7. What is the breakup of the global glioblastoma multiforme treatment market based on the distribution channel?
8. What are the key regions in the global glioblastoma multiforme treatment market?
9. Who are the key players/companies in the global glioblastoma multiforme treatment market?
Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.
Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs.
These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global glioblastoma multiforme treatment market report, along with forecasts at the global and regional level from 2024-2032. The report has categorized the market based on drug type, route of administration, type of molecule, and distribution channel.Breakup by Drug Type:
- Temozolomide
- Bevacizumab
- Carmustine
- Radiosensitizers
- Others
Breakup by Route of Administration:
- Oral
- Parenteral
Breakup by Type of Molecule:
- Small Molecule
- Biologics
Breakup by Distribution Channel:
- Hospitals
- Pharmacies
- Others
Breakup by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Competitive Landscape
The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.This report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.
Key Questions Answered in This Report
1. What was the size of the global glioblastoma multiforme treatment market in 2023?2. What is the expected growth rate of the global glioblastoma multiforme treatment market during 2024-2032?
3. What are the key factors driving the global glioblastoma multiforme treatment market?
4. What has been the impact of COVID-19 on the global glioblastoma multiforme treatment market?
5. What is the breakup of the global glioblastoma multiforme treatment market based on the route of administration?
6. What is the breakup of the global glioblastoma multiforme treatment market based on the type of molecule?
7. What is the breakup of the global glioblastoma multiforme treatment market based on the distribution channel?
8. What are the key regions in the global glioblastoma multiforme treatment market?
9. Who are the key players/companies in the global glioblastoma multiforme treatment market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Glioblastoma Multiforme Treatment Market
6 Market Breakup by Drug Type
7 Market Breakup by Route of Administration
8 Market Breakup by Type of Molecule
9 Market Breakup by Distribution Channel
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Sun Pharmaceutical Industries
- Celldex Therapeutics
- Pfizer
- F. Hoffmann La Roche
- Bristol-Myers Squibb
- Teva Pharmaceuticals
- Exelixis
- Angiochem
- Arbor Pharmaceuticals
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 2.1 Billion |
| Forecasted Market Value ( USD | $ 3.9 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
